WO2004105870A1 - 心臓治療装置及び心臓治療方法 - Google Patents
心臓治療装置及び心臓治療方法 Download PDFInfo
- Publication number
- WO2004105870A1 WO2004105870A1 PCT/JP2004/007568 JP2004007568W WO2004105870A1 WO 2004105870 A1 WO2004105870 A1 WO 2004105870A1 JP 2004007568 W JP2004007568 W JP 2004007568W WO 2004105870 A1 WO2004105870 A1 WO 2004105870A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tachycardia
- treatment
- heart
- stimulation
- nerve
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/3621—Heart stimulators for treating or preventing abnormally high heart rate
- A61N1/3622—Heart stimulators for treating or preventing abnormally high heart rate comprising two or more electrodes co-operating with different heart regions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/38—Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
- A61N1/39—Heart defibrillators
- A61N1/3956—Implantable devices for applying electric shocks to the heart, e.g. for cardioversion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/38—Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
- A61N1/39—Heart defibrillators
- A61N1/395—Heart defibrillators for treating atrial fibrillation
Definitions
- the present invention relates to a cardiac treatment device for preventing and treating fatal arrhythmias, and more particularly to a cardiac treatment device and a cardiac treatment method capable of controlling tachycardia preventive treatment after anti-tachycardia treatment.
- sudden cardiac deaths Of the sudden deaths, especially those caused by heart disease, are called sudden cardiac deaths, the number of which is about 50,000 annually in the country.
- the immediate cause of sudden cardiac death is the development of hemodynamically disrupted ventricular tachycardia—ventricular fibrillation, called lethal arrhythmias.
- ventricular tachycardia the ventricle pulsates abnormally prematurely, and in the case of ventricular fibrillation, the individual muscle fibers constituting the ventricle begin to be disorderly excited and the whole ventricle trembles only in small steps Fatal arrhythmia When this occurs, the pump function of the heart is reduced or lost, and it becomes impossible to pump necessary blood to the whole body, causing a loss of consciousness due to a decrease in cerebral blood flow. If they do, they can die.
- ICD Implantable cardioverter-defibrillators
- ICD performs defibrillation by giving an electric shock to the heart when the occurrence of ventricular tachycardia / ventricular fibrillation is detected.
- ICD is a treatment device that operates after an abnormality has occurred in the heart, so to speak, is a coping therapy, and a large electric shock for defibrillation puts a burden on the heart tissue.
- cardiac activity is governed by the autonomic nervous system, but the autonomic nervous system has a sympathetic nervous system and a parasympathetic nervous system.
- the system is the vagus nerve.
- Increased sympathetic activity increases cardiac activity (heart rate and cardiac output), and increased vagal activity decreases cardiac activity (heart rate).
- These sympathetic and vagal activities are usually antagonized, but if the sympathetic tone is excessively increased and its paralysis is disrupted, the motility of the heart muscle and the conduction system is increased.
- organic heart diseases such as myocardial infarction and cardiomyopathy, the combination of organic heart lesions and increased sympathetic tone increases the likelihood of fatal arrhythmias.
- Methods to prevent the occurrence of such lethal arrhythmias include directly stimulating the transmission of excessive sympathetic tone to the heart by electrically stimulating sympathetic nerves, and the vagus nerve.
- This cardiac therapy device provides a prophylactic activation current to the vagus nerve, supplies an inhibitory current to the sympathetic nerve, and immediately detects vaginosis when detecting chronic fibrillation or other dangerous tachyarrhythmias. Lightly activate nerves for 5 seconds. Then, when the return to the normal state is detected, the treatment ends, but when the abnormal state with respect to the heart is continuously detected, the treatment is continued. And if it is advantageous to block the conduction of sympathetic stimulation from the brain, additionally perform this block in the stellate ganglion for a few seconds. Nevertheless, abnormal heart condition If an electric shock is detected, an electric shock is supplied by a conventional method.
- Patent Document 1 Japanese Patent Application Laid-Open No. Hei 8 _ 8 8 6 25
- Patent Document 2 U.S. Patent No. 6,487,450
- the cardiac treatment apparatus described in Patent Document 1 does not include a mechanism for reducing or stopping the activation current for the vagus nerve or the suppression current for the sympathetic nerve after the supply of the electric shock to the heart.
- problems such as deterioration of hemodynamics, recurrence of fatal arrhythmia, and supraventricular arrhythmia such as atrial fibrillation.
- the arrhythmia treatment device described in Patent Document 2 does not include a control mechanism for reducing nerve stimulation energy or stopping nerve stimulation following arrhythmia arrest treatment, and thus is similar to the heart treatment device described in Patent Document 1
- problems such as deterioration of hemodynamics, recurrence of fatal arrhythmias, and supraventricular arrhythmias such as atrial fibrillation have not yet been solved. Disclosure of the invention
- the present invention takes into account that the heart after anti-tachycardia treatment is in an unstable state, and to apply a preventive treatment that acts on the heart in such a situation, Considering the above-mentioned problems such as deterioration of dynamics, recurrence of fatal arrhythmias, and supraventricular arrhythmias such as atrial fibrillation.
- a heart treatment apparatus and a heart treatment method capable of shifting to a mode in which tachycardia preventive treatment is stopped and nerve stimulation energy is small in response to detection of tachycardia or confirmation of continuation of tachycardia. With the goal.
- a heart treatment apparatus of the present invention includes a tachycardia preventing means for preventing the occurrence of tachycardia, and a tachycardia for detecting the occurrence of tachycardia.
- Detecting means tachycardia stopping means for supplying anti-tachycardia treatment for stopping the tachycardia in response to the tachycardia detecting means, and control means connected to the tachycardia preventing means and the tachycardia detecting means.
- the control means controls the tachycardia prevention means to stop operating in response to the tachycardia detection means.
- the present invention provides a tachycardia prevention means for preventing tachycardia from occurring, a tachycardia detecting means for detecting the occurrence of tachycardia, and a tachycardia continuing in response to the tachycardia detecting means.
- a tachycardia checking means for confirming that the tachycardia is stopped;
- a tachycardia stopping means for supplying an anti-tachycardia treatment for stopping the tachycardia in response to the tachycardia checking means;
- Control means for connection, wherein the control means controls to stop the tachycardia prevention means in response to the tachycardia confirmation means.
- a preferred embodiment of the present invention includes a nerve stimulating means for stimulating a sympathetic nerve (stellate ganglion) or a parasympathetic nerve (vagus nerve) as a means for preventing tachycardia.
- the stimulation of the sympathetic nerve is a stimulation that does not increase the heart rate and blood pressure, or the stimulation that blocks the conduction of the sympathetic nerve excitation, and the stimulation of the parasympathetic nerve activates the parasympathetic nerve excitation It is characterized by being a thing.
- the anti-tachycardia treatment provided by the tachycardia arresting means includes anti-tachycardia pacing, cardioversion, It is characterized by including at least one defibrillation.
- a preferred embodiment of the present invention includes a bradycardia detecting means for detecting the occurrence of bradycardia and a bradycardia treatment means for generating a cardiac stimulation pulse in response to the bradycardia detecting means.
- a timing means for measuring a predetermined time is provided, and the timing means responds to the supply of the anti-tachycardia treatment by the tachycardia stopping means. This is to set a timing time suitable for anti-tachycardia treatment.
- a tachycardia stop confirming means for confirming whether or not the tachycardia has been stopped by the tachycardia stopping means, and timing is provided in response to the tachycardia stop confirming means. It is characterized in that tachycardia preventive treatment is performed by the control means after the means measures a predetermined time.
- a tachycardia stop confirming means for confirming whether or not the tachycardia has been stopped by the tachycardia stopping means, and in response to the tachycardia stop confirming means, It is characterized in that tachycardia preventive treatment is performed by the control means after measuring the time suitable for the supplied anti-tachycardia treatment or after the measured heart rate exceeds a predetermined threshold.
- the present invention provides a tachycardia preventing means for preventing tachycardia from being generated by nerve stimulation, a tachycardia detecting means for detecting the occurrence of tachycardia, and a tachycardia in response to the tachycardia detecting means.
- a tachycardia stopping means for supplying an anti-tachycardia treatment for stopping, and a control means connected to the tachycardia prevention means and the tachycardia detection means. It is operated in the operation mode and the second operation mode, and the nerve stimulation energy of the second operation mode is set to be smaller than the nerve stimulation energy of the first operation mode.
- the control means may operate the tachycardia prevention means in the second operation mode in response to the tachycardia detection means. It is characterized by the following.
- the present invention also provides a tachycardia preventing means for preventing tachycardia from occurring due to nerve stimulation, a tachycardia detecting means for detecting tachycardia occurrence, and the tachycardia in response to the tachycardia detecting means.
- Tachycardia checking means for checking that tachycardia continues, tachycardia stopping means for supplying anti-tachycardia therapy for stopping the tachycardia in response to the tachycardia checking means, tachycardia prevention means and the tachycardia Control means connected to the pulse confirmation means, wherein the neural stimulation by the tachyarrhythmia prevention means is activated in at least the first operation mode and the second operation mode, and the second operation mode is provided.
- the control means operates the tachycardia prevention means in the second operation mode in response to the tachycardia confirmation means so that the nerve stimulation energy of the first mode is set smaller than the nerve stimulation energy of the first operation mode. It is characterized by
- the present invention is also provided as an invention of a heart treatment method having similar features in relation to the technical features of the heart treatment device described above.
- a mechanism for reducing or stopping the activation current for the vagus nerve or the suppression current for the sympathetic nerve after the supply of the electric shock to the heart such as cardioversion and defibrillation. It can prevent the occurrence of supraventricular arrhythmias such as hemodynamic deterioration, fatal arrhythmias, and atrial fibrillation.
- supraventricular arrhythmias such as hemodynamic deterioration, fatal arrhythmias, and atrial fibrillation.
- tachycardia or confirmation of continuation of tachycardia there is a risk of sudden cardiac death because the mode shifts to a mode in which tachycardia prophylactic treatment is stopped and nerve stimulation energy is reduced. It is possible for patients to prevent and treat fatal arrhythmias such as tachycardia, which is reasonable for patients.
- FIG. 1 is a block diagram showing a configuration example of a first embodiment of the heart treatment apparatus of the present invention.
- FIG. 2 is a diagram showing the arrangement of electrode leads and stimulating electrodes used in the heart treatment apparatus of the present invention on the heart.
- FIG. 3 is a flowchart for explaining the operation of the first embodiment of the present invention.
- FIG. 4 is a flowchart for explaining the operation of the first embodiment of the present invention.
- FIG. 5 is a block diagram showing a configuration example of a second embodiment of the heart treatment apparatus of the present invention.
- FIG. 6 is a flowchart for explaining the operation of the second embodiment of the present invention.
- FIG. 7 is a flowchart for explaining the operation of the second embodiment of the present invention.
- FIG. 8 is a block diagram showing a configuration example of a third embodiment of the heart treatment apparatus of the present invention.
- FIG. 9 is a flowchart for explaining the operation of the third embodiment of the present invention.
- FIG. 10 is a flowchart for explaining the operation of the third embodiment of the present invention.
- FIG. 11 is a block diagram showing a configuration example of a fourth embodiment of the heart treatment apparatus of the present invention.
- FIG. 12 is a flowchart for explaining the operation of the fourth embodiment of the present invention.
- FIG. 13 is a flowchart for explaining the operation of the fourth embodiment of the present invention.
- FIG. 14 is a block diagram showing a configuration example of a fifth embodiment of the heart treatment apparatus of the present invention.
- FIG. 15 is a flowchart for explaining the operation of the fifth embodiment of the present invention.
- FIG. 16 is a flowchart for explaining the operation of the fifth embodiment of the present invention.
- the heart treatment device 1 of the present invention includes a cardiac contraction detection unit 2 that detects contraction of the heart 38, a tachycardia detection unit 3 that constantly monitors the output of the cardiac contraction detection unit 2 and detects tachycardia, A tachycardia checker 4 that checks the recurrent detection of tachycardia, a tachycardia stop checker 5 that checks that tachycardia has been stopped by anti-tachycardia treatment, and a vagus nerve 4 1 or sympathetic nerve 4 5
- the tachycardia prevention unit 6 that stimulates the stellate nerve node 4 4 to prevent tachycardia, and the control unit 7 and the control unit 7 that perform control to stop or activate the operation of the tachycardia prevention unit 6
- a timing section 8 for determining the timing of switching the operation of the tachycardia prevention section 6; a bradycardia treatment section 9 for performing bradycardia treatment when the cardiac contraction detection section 2 detects brady
- the tachyarrhythmia prevention unit 6 is composed of two means, a sympathetic nerve stimulating unit 13 that supplies a stimulus signal to the stellate ganglion 44 and a parasympathetic nerve stimulating unit 14 that supplies a stimulus signal to the vagus nerve 41. It is operated by a tachycardia prevention program.
- the sympathetic nerve stimulating section 13 is composed of a block stimulating section 15 and a sub-threshold stimulating section 16, and the parasympathetic nerve stimulating section 14 is composed of an activation stimulating section 17.
- the block stimulator 15 stimulates the sympathetic tone, which increases the risk of tachycardia development, from the brain.
- the sub-threshold stimulating unit 16 is used to prevent the heart 38 from transmitting to the heart 38, especially when the heart 38 has a structure in which tachycardia is likely to occur, such as after myocardial infarction.
- a weak stimulus to the stellate ganglion 44 that does not increase the number or blood pressure, and by stimulating neurogenesis in the sinus node (not shown) and ventricular muscle, tachycardia is unlikely to occur. It restructures the heart 38 into a structure.
- the sub-threshold stimulating unit 16 operates, and when an increase in sympathetic tone, such as an increase in heart rate, is detected, the block stimulating unit 15 operates to block this.
- the activation stimulating unit 17 of the parasympathetic stimulating unit 14 stimulates the vagus nerve 41 by detecting an increase in the sympathetic tone such as an increase in the heart rate, and antagonistically suppresses the sympathetic tone and increases the heart rate.
- the oxygen consumption of the L, organ 38 is reduced, thereby reducing the risk of tachycardia occurrence.
- the control unit 7 receives a signal from the tachycardia detection unit 3 or the tachycardia confirmation unit 4 and stops the preventive treatment by the tachycardia prevention unit 6, and receives a signal from the timing unit 8. It comprises an activation unit 19 that allows the tachycardia prevention unit 6 to perform preventive treatment.
- the output of the stop section 18 and the activation section 19 is supplied to one of the block stimulating section 15, the subthreshold stimulating section 16 and the activation stimulating section 17 in the tachycardia prevention section 6. .
- the timing unit 8 includes a tachycardia preventive treatment switching timer 20 that starts timing by the output of the tachycardia stop confirmation unit 5 that confirms the stop of the tachycardia, and a tachycardia preventive treatment based on the confirmation of the tachycardia stop.
- the switching time storage unit 21 for storing the time until the start of the operation, and the control unit when the time measured by the tachycardia preventive treatment switching timer 20 reaches the time stored in the switching time storage unit 21. 7 and a comparison unit 22 that outputs an output to an activation unit 19.
- the bradycardia treatment unit 9 is a so-called pacemaker
- the first bradycardia treatment unit 23 that performs bradycardia treatment during normal times and the first bradycardia treatment unit 23 are Stimulation rate ⁇ Stimulation parameters such as stimulation voltage are different, bradycardia therapy switching to start timekeeping with output of 2nd bradycardia therapy section 24 that performs bradycardia therapy after tachycardia stop and tachycardia stop confirmation section 5
- a timer 25 a bradycardia treatment switching time storage unit 26 for storing a time for switching bradycardia treatment after the stop of tachycardia from the second bradycardia treatment unit 24 to the first bradycardia treatment unit 23,
- a comparison unit 27 that outputs when the time counted by the bradycardia treatment switching timer 25 reaches the time stored in the bradycardia treatment switching time storage unit 26, and a signal from the comparison unit 27 It comprises a bradycardia treatment selection unit
- the tachycardia stopping unit 12 includes an anti-tachycardia pacing unit 30 that is effective for slow tachycardia, and a cardio purge yoon unit 31 that supplies DC current to fast tachycardia in synchronization with cardiac contraction detection.
- Defibrillator 32 that applies DC current to fibrillation, anti-tachycardia pacing unit 30, cardioversion unit 31, and defibrillator 3 based on the output of tachycardia detector 3.
- an anti-tachycardia treatment output switching unit 33 for selecting either one of the two.
- the anti-tachycardia pacing unit 30 responds to the relatively slow tachycardia at a higher rate than the detected tachycardia after a predetermined connection time from the detection of cardiac contraction.
- the heart 38 is stimulated by being connected to the pacing pulse generator 10 via the anti-tachycardia treatment output switching unit 33.
- the cardioversion unit 31 applies DC power to relatively fast tachycardia in synchronization with cardiac contraction detection.
- This DC power supply causes the anti-tachycardia therapy output switching unit 33 to operate. It is connected to the shock pulse generator 11 via Then, the defibrillator 32 applies DC power to fibrillation. At this time, if possible, DC power is applied in synchronization with cardiac contraction detection.
- This DC current is connected to the shock pulse generator 11 via the anti-tachycardia therapy output switch 33 as in the Calgio version. Done.
- the anti-tachycardia therapy output switching unit 33 responds to the output of the tachycardia detection unit 3 to switch the selected therapy to the pacing pulse generator 10 or the shock pulse generator 11. Switching means for switching to and connecting to.
- the pacing pulse generator 10 generates a stimulus output for bradycardia therapy and anti-tachycardia pacing therapy, and usually has a pulse width of 1 ms ec. Is issued. Since the stimulation threshold is high during tachycardia, the stimulation output of anti-tachycardia pacing treatment is set higher than that of normal bradycardia treatment.
- the shock pulse generator 11 is used as a stimulus output for cardioversion treatment and defibrillation treatment.In general, 0.1 to 5 joules of energy are used in cardioversion. In defibrillation, up to 30 joules of energy are emitted as monophasic or biphasic panoles with a pulse width of 6 ms ec.
- FIG. 2 shows the positional relationship between the cardiac stimulation / detection electrode 35 and the shock pulse supply electrode 37 in the heart.
- FIG. 2 shows an example in which a cardiac stimulation / detection electrode 35 and a shock pulse supply electrode 37 are arranged by a catheter electrode.
- the catheter electrode is guided from the vena cava to the right atrium of the heart 38, enters the right ventricle through the atrioventricular valve, and is indwelled so that the tip of the catheter contacts the lowermost part of the right ventricle.
- This catheter electrode is covered with a sheath made of biocompatible silicon urethane or the like, and the inside thereof passes through a cardiac electrode lead 34 and a cardiac electrode lead 36 which are electrically insulated from each other.
- a cardiac stimulation detection electrode 35 It is placed and connected to a cardiac electrode lead 34.
- shock pulse supply electrodes 37 each having a large surface area are arranged in portions of the catheter electrode located in the right ventricle and the right atrium to the vena cava, and are connected to the heart electrode lead 36.
- the shock pulse supply electrode 37 has a coil-like structure, and can be placed in the heart flexibly.
- the heart detection electrode 35 located at the bottom of the right ventricle constantly monitors the activity of the heart to detect ventricular tachycardia / ventricular fibrillation.
- the cardiopurgeon treatment or defibrillation treatment by the shock pulse generator 11 is performed between the two electrodes or between the shock pulse supply electrode 37 and the case of the heart treatment device 1 (not shown).
- the parasympathetic nerve stimulation section 14 of the tachyarrhythmia prevention section 6 is connected to the vagus nerve stimulation electrode 40 via the parasympathetic nerve electrode lead 39, and the sympathetic nerve stimulation section 13 is also connected to the sympathetic nerve electrode lead. It is connected to sympathetic nerve stimulation electrode 4 3 via 4 2.
- the vagus nerve stimulation electrode 40 is fixed while being wound around the vagus nerve 41.
- the area around which the vagus nerve stimulation electrode 40 is wound is the cervical area or the right middle of the lateral carotid artery. The central position is preferred.
- the sympathetic nerve stimulation electrode 43 is wrapped around the body, which is the thick part of the stellate stellate ganglion 44, and is fixed to the cardiac nerve 45 coming out of the stellate ganglion 44. It is also possible to directly wrap and stimulate.
- the heart contraction detector 2 detects contraction of the heart (ventricle).
- the information on the cardiac contraction detected by the cardiac contraction detection unit 2 is sent to the tachycardia detection unit 3, the tachycardia confirmation unit 4, the tachycardia stop confirmation unit 5, and the bradycardia treatment unit 9 It is also supplied to the pulse prevention unit 6 and tachycardia stop unit 12.
- the tachycardia detector 3 monitors the output of the cardiac contraction detector 2 to detect tachycardia and classifies the tachycardia according to the degree of tachycardia.Anti-tachycardia treatment corresponding to the classified tachycardia situation Is selected. That is, the tachycardia which is a heartbeat equal to or higher than the predetermined rate detected by the tachycardia detector 3 is further classified into tachycardia and fibrillation according to the magnitude of the rate.
- tachycardia is divided into slow tachycardia and fast tachycardia, anti-tachycardia pacing treatment for slow tachycardia, cardioversion treatment for fast tachycardia, and defibrillation for fibrillation. Dynamic treatment is given accordingly.
- the association of tachycardia detection, classification, and treatment methods includes rate stability (whether the rate of tachycardia is stable) and suddenness (whether the tachycardia suddenly occurred or not. It is also possible to add criteria such as QRS width etc.
- anti-tachycardia treatment from tachycardia detector 3 to tachyarrhythmia stop 1 2
- a command to switch to the selected anti-tachycardia therapy is sent to the output switching section 33.
- the selected anti-tachycardia therapy is anti-tachycardia pacing
- the anti-tachycardia therapy is performed.
- the output is sent from the output switching unit 33 to the pacing pulse generation unit 10 and also to the tachyarrhythmia stop confirmation unit 5 to confirm the stop of the tachycardia.
- a rapid tachycardia is detected by the tachycardia detector 3
- cardiopurgeon treatment is performed, and if fibrillation is detected, defibrillation treatment is performed.
- the output of the heart contraction detection unit 2 is monitored, and the shock pulse generation unit 11 detects the predetermined amount of energy corresponding to the cardiopurge ion treatment or defibrillation treatment until the capacitor (not shown) is charged.
- a process is required in which the tachycardia checking unit 4 checks whether the detected tachycardia is sustained.
- charging time for cardioversion treatment is 1-2 seconds, and defibrillation treatment takes 7-9 seconds.
- the tachycardia detector 4 and the tachycardia arrestor 12 A command to perform the cardiopurgeon treatment or defibrillation treatment is sent to the treatment output switching unit 3 3, and the tachycardia prevention unit 6 is stopped for the stop unit 18 of the control unit 7. A command is sent.
- the selected force is issued to the anti-tachycardia therapy output switching section 33 of the tachycardia arresting section 12 to cancel the selected version therapy or defibrillation therapy. Is sent.
- the tachyarrhythmia stop confirming unit 5 receives the signal indicating the execution of the selected antitachyarrhythmia treatment from the antitachycardia treatment output switching unit 33 of the tachycardia stop unit 12 and monitors the output of the cardiac contraction detecting unit 2. Then, when it is confirmed that the detected tachycardia has stopped, the tachycardia preventive therapy switching timer 20 of the timing section 8 and the bradycardia therapy switching timer 25 of the bradycardia therapy section 9 are started. .
- the stop unit 18 of the control unit 7 When receiving the tachycardia prevention stop command from the tachycardia detector 3 or the tachycardia detector 4, the stop unit 18 of the control unit 7 sends a signal to the tachycardia prevention unit 6 to cause the activation stimulating unit 17 to stray.
- the stimulation of the nerve 41 and the stimulation of the stellate ganglion 44 by the block stimulating unit 15 and the subthreshold stimulating unit 16 are stopped.
- the anti-tachycardia therapy output switching section 33 of the tachycardia stopping section 12 obtains the output from the tachycardia detecting section 3 or the tachycardia checking section 4 and outputs the tachycardia detected by the tachycardia detecting section 3.
- Anti-tachycardia pacing therapy, cardiopurgeon therapy, or defibrillation therapy is selected according to the classification of the anti-tachycardia pacing therapy.
- Supply to pacing pulse generator 10 When the command from the tachycardia detector 3 is a cardioversion therapy or a defibrillation therapy, the anti-tachycardia therapy output switching section 33 selects the output of the cardioversion section 31 or the defibrillator 32. And supplies the shock pulse to the shock pulse generator 11.
- the anti-tachycardia therapy output switching unit 33 connects the anti-tachycardia pacing unit 30 to the pacing pulse generation unit 10 immediately when the anti-tachycardia pacing therapy is selected. Initiate pulse paging therapy.
- the cardioversion unit 31 or the defibrillation unit 32 is connected to the shock pulse generation unit 11 and the shock pulse generation unit 11 is connected to each treatment.
- the energy corresponding to is set and charging is started.
- the tachycardia checking unit 4 notifies that the tachycardia has been stopped, a charging stop command and an internal discharging command are issued to the shock pulse generating unit 11.
- the bradycardia treatment unit 9 performs normal bradycardia treatment differently from bradycardia treatment after confirmation of tachycardia arrest, and the first bradycardia treatment is performed as the normal bradycardia treatment.
- a treatment unit 23 is used.
- the first bradycardia treatment unit 23 when the output of the cardiac contraction detection unit 2 falls below the predetermined rate, It has the function of a normal pacemaker that stimulates the heart 38 at a given rate. In this case, the heart 38 is stimulated by the pacing pulse generator 10 via the bradycardia therapy selector 28.
- the bradycardia treatment after confirming the stop of the tachycardia is performed by the second bradycardia treatment section 24.
- the second bradycardia therapy section 24 prepares for the first bradycardia therapy section in preparation for an increase in the stimulation threshold of the heart 38 (the stimulation energy necessary to beat the heart 38) after the anti-tachycardia treatment.
- the stimulus output is set higher than the normal bradycardia treatment performed in 23.
- the bradycardia treatment selection section 28 switches between the first bradycardia treatment section 23 and the second bradycardia treatment section 24. That is, when the signal from the tachyarrhythmia stop confirming unit 5 is supplied to the bradycardia treatment switching timer 25, the bradycardia treatment switching timer 25 resets the contents of the previous time measurement and starts the time measurement. . Along with the start of the bradycardia treatment switching timer 25, the bradycardia treatment selection unit 28 selects the second bradycardia treatment unit 24 to perform the necessary bradycardia treatment after confirming the stoppage of the tachycardia.
- the comparison unit 27 outputs an output.
- the bradycardia therapy selection unit 28 switches from the second bradycardia therapy unit 24 to the first bradycardia therapy unit 23 that is a normal bradycardia therapy.
- the output signal of the comparison section 27 is also supplied to a bradycardia treatment switching timer 25, which stops the timing of the bradycardia therapy switching timer 25 and resets the content of the timing.
- the tachyarrhythmia stop confirmation signal from the tachyarrhythmia stop confirmation section 5 turns off the tachycardia preventive treatment of the timing section 8.
- the tachycardia preventive treatment switching timer 20 resets the contents of the previous time measurement and starts the time measurement.
- the comparison unit 22 reads the control unit 7. An output is issued to the activation unit 19 and the tachycardia prevention treatment by the tachycardia prevention unit 6 is restarted.
- the output signal of the comparison section 22 is also supplied to the tachycardia preventive treatment switching timer 20, and the timer of the tachycardia preventive treatment switching timer 20 is stopped and the content of the timer is also measured. Reset 0
- the tachycardia prevention treatment program of the tachycardia prevention unit 6 is activated by a signal from the activation unit 19 of the control unit 7 (step S 1), and the tachycardia is Write True to the tachycardia preventive / treatment active flag (not shown) of the preventive unit 6 (step S2).
- the tachycardia preventive treatment switching timer 20 is stopped / reset (step S3), and in the bradycardia treatment section 9, the first pulse is given by the bradycardia treatment selection section 28.
- the bradycardia treatment switching timer 25 is stopped / reset (step S4). S5). '
- step S6 it is determined whether or not the bradycardia is detected by the cardiac contraction detecting section 2 (step S6). If the bradycardia is detected, the pacing pulse generating section 10 outputs the heartbeat. Bradycardia therapy is supplied to 38 (step S7). If the bradycardia is not detected in the judgment step S6, it is then determined whether the tachycardia is detected by the tachycardia detector 3 (step S8), and the tachycardia is detected. If detected, a signal is sent to the tachycardia arrest unit 12, and a tachyarrhythmia arrest treatment corresponding to the detected tachycardia is selected from anti-tachycardia pacing, cardioversion, and defibrillation. Is selected (step S9). Then go to 1A in Figure 4.
- step S10 If bradycardia therapy is supplied in step S7 or tachycardia is not detected in determination step S8, whether tachycardia preventive therapy switching timer 20 of timing unit 8 has timed out Is determined (step S10). If the tachycardia preventive treatment switching timer 20 has timed out, that is, if the tachycardia preventive treatment switching timer 20 has timed beyond the time stored in the switching time storage unit 21, the control unit 7 A signal is sent to the activation section 19 of the tachycardia preventive treatment program by activating the tachycardia preventive treatment program (step S11), and the tachycardia preventive treatment active flag of the tachycardia preventive section 6 is set to True. Write (step S12), and then stop / reset the tachycardia preventive treatment switching timer 20 (step S13).
- the tachycardia preventive treatment switching timer 20 is stopped in step S13.
- the bradycardia treatment switching timer 25 in the bradycardia treatment unit 9 has timed out, that is, the bradycardia treatment switching timer 25 is stored in the bradycardia treatment switching time storage unit 26
- it is determined whether or not the time has been counted over the set time step S14.
- the process returns to the selection of the first bradycardia treatment mode in step S4, and the bradycardia treatment switching timer 25 has timed out. If not, wait for the detection of a new bradycardia in decision step S6.
- step S9 the operation of the first embodiment of the present invention after the selection of the tachyarrhythmia arrest treatment in step S9 will be described based on the flowchart of FIG.
- Step S15 it is determined whether or not the anti-tachycardia pacing treatment is selected as the anti-tachycardia treatment (tachyarrhythmia treatment) in the tachyarrhythmia stopping unit 1 2 (Step S15).
- the stop unit 18 of the control unit 7 is operated to stop the tachycardia prevention treatment of the tachycardia prevention unit 6 (step S1).
- step S19 it is next determined whether or not the cardioversion treatment is selected.
- the anti-tachycardia treatment output switching unit 33 of the tachycardia stop unit 12 connects the cardioversion unit 31 and the shock pulse generation unit 11 and the shock pulse generation unit 1 1 A predetermined amount of energy corresponding to the Cardioversion treatment is charged to the capacitors.
- the tachycardia checking unit 4 checks whether or not the tachycardia continues (step S20).
- step S 21 False is written in the tachycardia preventive treatment active flag of the tachycardia preventive unit 6 (step S 22), and subsequently, the cardioversion connected by the anti-tachycardia treatment output switching unit 33.
- the cardioversion treatment by the control unit 31 is supplied to the heart 38 via the shock pulse generating unit 11 (step S23).
- the anti-tachycardia therapy output switching section 33 of the tachycardia stop section 12 connects the defibrillation section 32 and the shock pulse generation section 11 and the shock pulse generation section 11
- the capacitor is charged with a predetermined energy amount corresponding to the defibrillation treatment.
- the tachycardia checking unit 4 checks whether the tachycardia continues (step S25).
- the stop unit 18 of the control unit 7 is operated to stop the tachycardia prevention treatment of the tachycardia prevention unit 6 (step S10). 2 6), writes False in the tachycardia prevention treatment active flag of the tachycardia prevention unit 6 (step S 27), and then the defibrillation unit 32 connected by the anti-tachycardia treatment output switching unit 33. Defibrillation therapy is supplied to the heart 38 via the shock pulse generator 11 (step S28).
- step S30 After the anti-tachycardia pacing treatment in step S18, the cardioversion treatment in step S23, or the defibrillation treatment in step S28 is supplied to the heart 38, the tachycardia arrest is confirmed.
- step S29 it is determined whether or not the tachycardia has stopped. If it is confirmed that the tachycardia has stopped, the tachycardia preventive treatment switching timer 20 of the timing section 8 is reset (Step S30), and then the bradycardia treatment is started.
- the bradycardia treatment switching timer 25 of the unit 9 is reset (Z-start) (step S31), and the bradycardia treatment selection unit 28 causes the second bradycardia treatment of the second bradycardia treatment unit 24.
- the mode is selected (step S32), and the process returns to the decision step S10 of FIG.
- the process returns to the step S9 in FIG. 3 to select the recurrent tachycardia arrest treatment.
- the applied energy is increased and the treatment for tachycardia arrest is changed in stages (for example, the treatment is changed from cardiopurgeon to defibrillation).
- step S30 If the continuation of tachycardia is not confirmed in the judgment step S20 and the judgment step S25, that is, when the shock pulse generator 11 If the tachycardia stops spontaneously while charging the battery, the charging is stopped and the charging energy is discharged internally, and the tachycardia stop section 12 and the cardiopurge section 31 or the defibrillator 32 and the shock pulse The connection with the generating unit 11 is released, and it is determined whether the tachycardia prevention treatment active flag of the tachycardia prevention unit 6 is True (step S33). If the tachycardia prevention treatment active flag is True, that is, if the tachycardia prevention treatment of the tachycardia prevention unit 6 is activated, the decision step S in FIG.
- tachycardia preventive treatment active flag is not True, that is, if tachycardia preventive treatment of tachycardia preventive unit 6 has not been activated, it is highly likely that the heart is still in an unstable state.
- step 5 the processing after step S30, which is the sequence after the stop of the tachycardia, is performed.
- FIG. 5 is a block diagram showing a second embodiment of the heart treatment apparatus of the present invention.
- the difference from the first embodiment shown in FIG. 1 is the configuration of the timing unit 8.
- Other configurations are the same as those in the block configuration diagram of FIG.
- the time from the confirmation of the stop of the tachycardia to the resumption of the tachycardia preventive treatment is stored in the switching time storage unit 21 irrespective of the state of the tachycardia.
- the time from the above-described confirmation of the stoppage of the tachycardia to the resumption of the tachycardia preventive treatment is classified into three stages according to the state of the tachycardia.
- the timing unit 8 in the second embodiment of the present invention includes a tachycardia preventive treatment switching timer 20 that starts timing by the output of the tachycardia stop confirmation unit 5 and an anti-tachycardia pacing.
- the first period storage unit 46 that stores the time from the confirmation of tachycardia arrest after treatment with anti-tachycardia treatment to the activation of the tachycardia prevention unit 6 and confirmation of tachyarrhythmia cessation after anti-tachycardia treatment with cardioversion treatment
- the second period storage unit 47 stores the time from activation to activation of the tachycardia prevention unit 6 and the tachyarrhythmia stop after anti-tachycardia treatment by defibrillation treatment.
- the switching time selection unit 49 which selects one of the third period storage units 48 and supplies it to the comparison unit 22, compares the switching time selected above with the time measured by the tachycardia preventive treatment switching timer 20. Then, when the time measured by the tachycardia preventive treatment switching timer 20 exceeds the selected storage time, the comparison unit 22 supplies a signal to the activation unit 19 of the control unit 7. Is done.
- the storage value of the third period storage unit 48 which is the switching time for defibrillation treatment, is stored in the second period storage unit 47 for cardiopurgeon and the first period storage unit 46 for anti-tachycardia pacing treatment.
- the stored value of the second period storage unit 47 which is longer than the stored value and the switching time for the cardiopurgeon treatment, is longer than the stored value of the first period storage unit 46 for anti-tachycardia pacing. It is set. This is because the stronger the energy applied to the heart, the longer the heart will become unstable.
- the switching time selector 49 selects the first period storage 4 according to the state of the tachycardia. 6. One of the second period storage unit 47 and the third period storage unit 48 is selected, and the selected time is used as the threshold value of the comparison unit 22.
- the tachycardia preventive treatment switching timer 20 starts measuring the time, and when the tachycardia reaches the threshold value selected above, the comparing section 22 Outputs an output to the activation unit 19 of the control unit 7 to restart the tachycardia prevention treatment by the tachycardia prevention unit 6.
- FIG. 6 The flow chart of FIG. 6 is the same as the flow chart of FIG. 3, except that the number of each step is different from that of the first embodiment. Therefore, the explanation includes the overlapping part.
- the tachycardia prevention unit 6 is activated by the signal from the activation unit 19 of the control unit 7 (step S34), and the tachycardia prevention unit 6 is not shown. Is written into the tachycardia preventive / treatment active flag (step S35).
- the tachycardia preventive treatment switching timer 20 is stopped / reset (step S36), and in the bradycardia treatment section 9, the bradycardia treatment selection section 2 is reset. 8 and select the first bradycardia treatment mode of the first bradycardia therapy section 23 (step S37). Stop / reset the bradycardia therapy switching timer 25 (step S37). S38).
- step S39 it is determined whether or not a bradycardia is detected by the cardiac contraction detecting section 2 (step S39). If the bradycardia is detected, the pacing pulse generating section 10 determines whether or not the bradycardia is detected. Bradycardia therapy is supplied to the heart 38 (step S40). If the bradycardia is not detected in the judging step S39, subsequently, it is determined whether the tachycardia is detected by the tachycardia detector 3 (step S41), and the tachycardia is detected.
- tachyarrhythmia treatment corresponding to the detected tachycardia is selected from among anti-tachycardia pacing, cardioversion, and defibrillation. Is selected (step S42). Then go to 2A in Figure 7.
- the tachycardia preventive therapy switching timer 20 of the timing unit 8 is activated. Is determined (step S43).
- the tachycardia preventive treatment switching timer 20 is timed, that is, the first period storage unit 46, the second period storage unit 47, or the third period storage unit selected by the switching time selection unit 49 4. If the tachycardia preventive treatment switching timer 20 counts for more than the time stored in any of 8, a signal is sent to the activation unit 19 of the control unit 7 to activate the tachycardia prevention treatment program.
- Step S44 write True to the tachycardia prevention / treatment active flag of the tachycardia prevention unit 6 (step S45), and then reset the tachycardia prevention / treatment switching timer 20 (step S45). S4 6).
- step S47 when it is determined that the tachycardia preventive treatment switching timer 20 is not timed in the judgment step S43, and in step S46, the tachycardia preventive treatment switching timer 20 is stopped / After the reset, whether or not the bradycardia treatment switching timer 25 in the bradycardia treatment unit 9 has timed out, that is, the bradycardia treatment switching timer 25 is stored in the bradycardia treatment switching time storage unit 26 It is determined whether or not the time has been counted beyond the set time (step S47).
- the process returns to the selection of the first bradycardia treatment mode in step S37, and the bradycardia treatment switching timer 25 times out. If not, judgment is made at step S39 to wait for the detection of a new bradycardia.
- step S48 it is determined whether or not the anti-tachycardia pacing treatment is selected as the anti-tachycardia treatment (tachyarrhythmia treatment) in the tachycardia arresting section 12 (step S48).
- the stop unit 18 of the control unit 7 is operated to stop the tachycardia prevention treatment program of the tachycardia prevention unit 6 (step S4).
- step S53 If the anti-tachycardia pacing is not selected in the judgment step S48, it is next judged whether or not the cardiopurgeon treatment is selected (step S53).
- the anti-tachycardia treatment output switching unit 33 of the tachycardia stop unit 12 connects the cardioversion unit 31 and the shock pulse generation unit 11 and the shock pulse generation unit 11 A predetermined amount of energy corresponding to the Cardioversion treatment is charged to the capacitors.
- the tachycardia checking unit 4 checks whether the tachycardia continues (step S54).
- step S55 False is written in the tachycardia preventive treatment active flag of the tachycardia prevention unit 6 (step S56), and subsequently, the switching time selection unit 49 of the timing unit 8
- step S57 the cardiopurgeon treatment by the cardioversion section 31 is performed.
- the pulse is supplied to the heart 38 via the clock pulse generator 11 (step S58).
- the anti-tachycardia therapy output switching unit 33 of the tachycardia stop unit 12 connects the defibrillation unit 32 and the shock pulse generation unit 11, and defibrillates the capacitor of the shock pulse generation unit 11. A predetermined amount of energy corresponding to the treatment is charged. Until the charging of the capacitor is completed, the tachycardia checking unit 4 checks whether or not the tachycardia continues (step S60).
- the tachycardia prevention unit 6 of the control unit 7 is operated to stop the tachycardia prophylaxis treatment program of the tachycardia prevention unit 6 (step S61). False is written to the tachycardia preventive treatment active flag (step S62), and then the switching time selecting unit 49 of the timing unit 8 sets the threshold time of the tachycardia preventive treatment switching timer 20 to the second time. After selecting the time stored in the three-period storage unit 48 (step S63), the defibrillation treatment by the defibrillation unit 32 is applied to the heart 38 via the shock pulse generation unit 11. Supply (step S64).
- the tachyarrhythmia stop confirming unit 5 determines whether or not the tachycardia has stopped (step S65).
- the tachycardia preventive treatment switching timer 20 of the timing section 8 is reset / started (step S66), and subsequently, Then, the bradycardia treatment switching timer 25 of the bradycardia treatment section 9 is reset and started (step S67), and the bradycardia treatment selection section 28 is used to reset the second bradycardia treatment section 24.
- step S68 Select the bradycardia treatment mode (step S68), and return to the judgment step S43 of FIG.
- the process returns to the step S42 of FIG. 6 to select the recurrent tachycardia stop treatment. Based on the treatment plan, the applied energy is increased and the treatment method for tachycardia arrest is changed in stages.
- step S69 If the continuation of the tachycardia is not confirmed in the judgment step S54 and the judgment step S60, that is, if the tachycardia stops spontaneously while charging the capacitor of the shock pulse generator 11, Stop of charging and internal discharge of charging energy, contact between tachycardia stopping section 12 cardioversion section 31 or defibrillation section 32 and shock pulse generation section 11 At the same time, the connection is canceled, and it is determined whether or not the tachycardia prevention / treatment active flag of the tachycardia prevention unit 6 is True (step S69).
- the process returns to the determination step S43 in FIG.
- the tachycardia prevention treatment active flag is not True, that is, if the tachycardia prevention treatment of the tachycardia prevention unit 6 has not been activated, it is highly likely that the heart is still in an unstable state.
- the processing after step S66 which is the sequence after the tachycardia arrest, is performed.
- the switching time selection unit 49 of the timing unit 8 stores the first period storage unit 46, the second period storage unit 47, or the third period storage corresponding to the tachycardia arrest treatment performed immediately before.
- the selection of one of the sections 48 is held, and the activation of the tachycardia prevention treatment of the tachycardia prevention section 6 is controlled based on the time stored in the selected storage section.
- FIG. 8 is a block diagram showing a third embodiment of the heart treatment apparatus of the present invention.
- the difference from the first embodiment of the present invention shown in FIG. 1 and the second embodiment shown in FIG. 5 is that a heart rate measuring unit 50 is provided instead of the timing unit 8.
- the other components are the same as those in the block diagrams of FIGS. 1 and 5, and thus are denoted by the same reference numerals and description thereof will be omitted.
- the heart rate measuring section 50 in the third embodiment of the present invention includes a heart rate measuring section 51 to which the output of the cardiac contraction detecting section 2 and the output of the tachyarrhythmia stop confirming section 5 are supplied, and a predetermined heart rate.
- the heart rate measurement unit 51 measures the heart rate detected by the cardiac contraction detection unit 2 after the tachycardia stop confirmation unit 5 confirms the tachycardia stop.
- the comparison section 53 sends an output to the activation section 19, thereby activating the tachycardia prevention section 6.
- tachycardia preventive treatment is performed.
- the tachycardia prevention treatment program of the tachycardia prevention unit 6 is activated by a signal from the activation unit 19 of the control unit 7 (step S 70), and the tachycardia prevention unit 6 Write True to the tachycardia preventive treatment active flag (step S71). Then, in the bradycardia treatment section 9, the first bradycardia treatment mode of the first bradycardia treatment section 23 is selected by the bradycardia treatment selection section 28 (step S72). Then, the bradycardia treatment switching timer 25 is stopped (step S73).
- step S74 it is determined whether or not the bradycardia is detected by the cardiac contraction detecting section 2 (step S74). If the bradycardia is detected, the pacing pulse generating section 10 outputs the heart 3 to the heart. 8, bradycardia treatment is supplied (step S75). If the bradycardia is not detected in the determination step S74, the tachycardia detector 3 determines whether the tachycardia is detected (step S76), and the tachycardia is detected.
- a signal is sent to the tachyarrhythmia stop unit 12 to select a tachyarrhythmia arrest treatment corresponding to the detected tachycardia from among anti-tachyarrhythmia pacing, cardioversion, and defibrillation. (Step S77), and proceed to 3A in FIG.
- the tachycardia prevention therapy active flag in tachycardia prevention unit 6 is True. It is determined whether or not this is the case (step S78). If the tachycardia prevention treatment active flag is not True, that is, if the tachycardia prevention treatment of the tachycardia prevention unit 6 is not activated, the heart rate is measured by the heart rate measurement unit 51 of the heart rate measurement unit 50. The heart rate is measured (step S79), and the measured heart rate is set to the heart rate threshold. It is determined whether the value is larger than the heart rate threshold value stored in the storage unit 52 (step S80).
- a control signal is sent to the activation section 19 of the control section 7 to perform tachycardia prevention treatment of the tachycardia prevention section 6 and (step).
- Step S81 the tachycardia prevention treatment active flag of the tachycardia prevention unit 6 is changed to True (step S82).
- bradycardia treatment switching in bradycardia treatment unit 9 is performed. It is determined whether or not the timer 25 has timed out, that is, whether or not the bradycardia treatment switching timer 25 has timed beyond the time stored in the bradycardia treatment switching time storage unit 26 (step S83).
- step S74 a new bradycardia detection is awaited.
- step S77 After 3A, the operation of the third embodiment of the present invention after the selection of the tachyarrhythmia arrest treatment in step S77 (after 3A) will be described with reference to the flowchart of FIG.
- step S84 it is determined whether or not the anti-tachycardia pacing treatment is selected as the anti-tachycardia treatment (tachyarrhythmia treatment) in the tachyarrhythmia stopping section 12 (step S84). If the anti-tachycardia pacing treatment is selected, the stop unit 18 of the control unit 7 is operated to stop the tachycardia prevention treatment program of the tachycardia prevention unit 6 (step S11).
- step S88 it is next determined whether or not the cardioversion treatment is selected.
- the anti-tachycardia treatment output switching unit 33 of the tachycardia stop unit 12 connects the cardioversion unit 31 and the shock pulse generation unit 11 and the shock pulse generation unit 1 1 A predetermined amount of energy corresponding to the cardioversion treatment is charged to the capacitors. Until the charging of the capacitor is completed, the tachycardia checking unit 4 checks whether the tachycardia continues (step S89).
- step S90 a signal is sent from the stop unit 18 of the control unit 7 to the tachycardia prevention unit 6 to stop the tachycardia prevention / treatment program.
- step S90 False is written in the tachycardia prevention treatment active flag of the tachycardia prevention unit 6 (step S91), and then the cardioversion unit 3 connected by the antitachycardia treatment output switching unit 3 3 The cardioversion treatment by 1 is supplied to the heart 38 via the shock pulse generator 11 (step S92).
- the anti-tachycardia therapy output switching unit 33 of the tachycardia stop unit 12 connects the defibrillation unit 32 and the shock pulse generation unit 11, and defibrillates the capacitor of the shock pulse generation unit 11. A predetermined amount of energy corresponding to the treatment is charged. Until the charging of this capacitor is completed, the tachycardia checking unit 4 checks whether or not the tachycardia continues (step S94).
- Step S95 Activates the stop unit 18 of the control unit 7 to stop the tachycardia prevention treatment of the tachycardia prevention unit 6 (step S95), and the tachycardia prevention treatment active flag of the tachycardia prevention unit 6 Is written to the heart (step S 966), and then the defibrillation treatment by the defibrillator 32 connected by the anti-tachycardia therapy output switching unit 33 is performed via the shock pulse generator 11. 3 8 (Step S97).
- step S87 After the anti-tachycardia pacing treatment in step S87, the cardiopurgeon treatment in step S92, or the defibrillation treatment in step S97 is supplied to the heart 38, the tachycardia arrest is confirmed.
- step S98 it is determined whether or not the tachycardia has stopped. If it is confirmed that the tachycardia has stopped, the bradycardia treatment switching timer 25 of the bradycardia treatment unit 9 is reset / started (step S99). Then, the second bradycardia treatment mode of the second bradycardia treatment section 24 is selected by the bradycardia treatment selection section 28 (step S100), and the procedure proceeds to the determination step S78 in FIG. Return.
- the procedure returns to the step S77 in FIG. 9 to select the recurrent tachycardia stop treatment. Based on the treatment plan, the applied energy is increased and the treatment method for tachycardia arrest is changed in stages.
- step S101 the active flag for tachycardia prevention treatment of the pulse prevention unit 6 is True (step S101). Then, the tachycardia prevention treatment active flag is True, that is, tachycardia prevention When the tachycardia prevention treatment of the part 6 is activated, the process returns to the determination step S83 of FIG.
- the tachycardia prevention treatment active flag is not True, that is, the tachycardia prevention of the tachycardia prevention part 6 is performed. If the treatment program has not been activated, it is highly probable that the heart is still in an unstable state, and the sequence after the stop of the tachycardia via the tachyarrhythmia stop confirming unit 5 is performed. Perform the processing from step 9 onward.
- FIG. 11 is a block diagram showing a fourth embodiment of the heart treatment apparatus according to the present invention.
- the difference from the first embodiment of the present invention shown in FIG. 1 is the configuration of the tachycardia prevention unit 6 and the control unit 7. That is, the tachycardia prevention unit 6 in this example is configured to perform only vagus nerve stimulation, and does not include means for stimulating the sympathetic nerve such as a stellate ganglion block.
- the other configuration is the same as that of the block configuration diagram in FIG. 1, and thus the same reference numerals are given and the description is omitted.
- a vagus nerve stimulation tachycardia prevention unit 55 is used in place of the tachycardia prevention unit 6 of the first embodiment.
- the vagus nerve stimulation tachycardia prevention unit 55 can generate a plurality of stimuli having different stimulation frequencies for the vagus nerve 41. That is, the vagus nerve stimulation tachycardia prevention unit 55 of the present example includes a first operation mode stimulation frequency storage unit 56 that stores the stimulation frequency f1 of the first operation mode, and a first operation mode
- the second operation mode stimulation frequency storage unit 57 stores the stimulation frequency f2 of the second operation mode having a frequency lower than the stimulation frequency f1, and the stimulation frequency f1 or the second mode of the first mode.
- the neural stimulation control unit 60 that controls the stimulation of the vagus nerve 41 by receiving the output of 2 and the parameters that are controlled by the nerve stimulation control unit 60 and set by the nerve stimulation parameter setting unit 59 are used. It comprises a nerve stimulating unit 6 1 that generates a nerve stimulating signal for the vagus nerve 4 1.
- control unit 7 includes a first control unit 62 that controls the selection unit 58 of the vagus nerve stimulation tachycardia prevention unit 55 according to the outputs of the tachycardia detection unit 3 and the tachycardia confirmation unit 4,
- the second control unit 63 receives the output from the comparison unit 22 of the timing unit 8 and supplies a signal to the selection unit 58 of the vagus nerve stimulation tachycardia prevention unit 55.
- the first control unit 62 of the control unit 7 controls the tachycardia.
- the selection unit 58 of the vagus nerve stimulation tachycardia prevention unit 55 is programmed to select the second operation mode stimulation frequency f2 and to stimulate the vagus nerve 41 with relatively weak energy.
- the comparing unit An output is sent from 22 to the second control section 63 of the control section 7, and the selection section 58 of the vagus nerve stimulation tachycardia prevention section 55 selects the stimulation frequency fl of the first operation mode.
- the vagus nerve 41 is stimulated with relatively strong energy.
- the stimulation frequency of the parameters of the nerve stimulation signal is changed to shift to the mode with the smallest stimulation energy.
- the parameters of the nerve stimulation signal are at least one of the following: stimulation frequency, pulse width, number of pulses, pulse current, pulse voltage, delay time, pause time, and number of repetitions.
- the selection unit 58 of the vagus nerve stimulation tachycardia prevention unit 55 selects the stimulation frequency ⁇ 1 of the first operation mode as an initial value, and stimulates the vagus nerve 41 with a stimulation waveform having a relatively high energy.
- Step S102 write True to a tachycardia preventive treatment mode flag (not shown) of the vagus nerve stimulation tachycardia prevention unit 55 (Step S103).
- the tachycardia preventive treatment switching timer 20 is stopped (step S104), and in the bradycardia treatment unit 9, the bradycardia treatment selection unit 28 sets the first ⁇ pulse.
- the first bradycardia treatment mode of the treatment section 23 is selected (step S105), and the bradycardia treatment switching timer 25 is reset (step S10). 6).
- step S107 it is determined whether or not a bradycardia is detected by the cardiac contraction detecting section 2 (step S107). If the bradycardia is detected, the pacing pulse generating section 10 determines whether or not the bradycardia is detected. The bradycardia therapy is supplied to the heart 38 (step S108). If the bradycardia is not detected in the determination step S107, then it is determined whether the tachycardia is detected by the tachycardia detector 3 (step S109), and the tachycardia is detected.
- a signal is sent to tachyarrhythmia stop section 12 to select tachyarrhythmia arrest therapy corresponding to the detected tachycardia from anti-tachycardia pacing, cardioversion, and defibrillation (Step S110). Then go to 4A in Figure 13.
- the tachycardia preventive therapy switching timer 20 of the timing unit 8 is timed out. It is determined whether or not the operation is performed (step S111). If the tachycardia preventive treatment switching timer 20 has timed out, that is, if the tachycardia preventive treatment switching timer 20 has timed out beyond the time stored in the switching time storage unit 21, the control unit 7 to the selector 5 8 via the second controller 6 3
- the stimulation frequency f 1 of the first operation mode is selected so as to give a relatively strong stimulation to the vagus nerve 41 (step S 1 1 2), and the vagus nerve stimulation tachycardia prevention section is selected. 5 True is written in the tachycardia preventive treatment mode flag of step 5 (step S113), and then the tachycardia preventive treatment switching timer 20 is stopped (step S114).
- step S111 when it is determined that the tachycardia preventive treatment switching timer 20 has not timed out in the judgment step S111, and the tachycardia preventive treatment switching timer 20 is stopped in step S114.
- the bradycardia treatment switching timer 25 in the bradycardia treatment unit 9 has timed out, that is, the bradycardia treatment switching timer 25 is stored in the bradycardia treatment switching time storage unit 26. It is determined whether or not the time has been counted beyond the time (step S115).
- the process returns to the selection of the first bradycardia treatment mode in step S105, and the bradycardia treatment switching timer 25 If has not timed out, the process waits for a new bradycardia detection in decision step S107.
- step S110 After the selection of the tachycardia arrest treatment in step S110 (after 4A) will be described with reference to the flowchart of FIG.
- step S116 it is determined whether or not the anti-tachycardia pacing treatment is selected as the anti-tachycardia treatment (tachyarrhythmia treatment) in the tachycardia stopping unit 12 (step S116).
- the anti-tachycardia pacing treatment is selected, the first control unit 62 of the control unit 7 is operated, and the selecting unit 58 of the vagus nerve stimulation tachycardia prevention unit 55 selects the second operation mode.
- the anti-tachycardia therapy output switching section 33 of the tachycardia stop section 12 is composed of the anti-tachycardia pacing section 30 and the pacing pulse generation section 10. To provide anti-tachycardia pacing to the heart 38 (step S119).
- step S120 If the anti-tachycardia paging is not selected in the judgment step S116, it is next judged whether or not the cardioversion treatment is selected (step S120).
- the anti-tachycardia therapy output switching section 33 of the tachycardia stopping section 12 connects the cardio purge section 31 to the shock pulse generating section 11 and the shock pulse generating section 1 1 A predetermined amount of energy corresponding to the cardioversion treatment is charged to the capacitors.
- the tachycardia checking unit 4 checks whether or not the tachycardia continues (step S 1 2 1), and that the tachycardia continues.
- a signal is sent from the first control unit 62 of the control unit 7 to the selection unit 58 of the vagus nerve stimulation tachyarrhythmia prevention unit 55, and the selection unit 58 selects the second operation mode. While the stimulation frequency f2 is selected (step S122), False is written to the tachyarrhythmia prevention treatment mode flag of the vagus nerve stimulation tachycardia prevention unit 55 (step S122), and then the The cardioversion treatment by the cardioversion unit 31 connected by the tachycardia treatment output switching unit 33 is supplied to the heart 38 via the shock pulse generation unit 11 (step S124).
- the anti-tachycardia therapy output switching section 33 of the tachycardia stopping section 12 connects the defibrillation section 32 and the shock pulse generation section 11 and removes the shock pulse generation section 11 capacitor. A predetermined amount of energy corresponding to the fibrillation treatment is charged. Until the charging of the capacitor is completed, the tachycardia checking unit 4 checks whether the tachycardia continues. (Step S126).
- a signal is sent from the first control unit 62 of the control unit 7 to the selection unit 58 of the vagus nerve stimulation tachycardia prevention unit 55, and the second When the stimulation frequency f2 of the operation mode is selected (step S127), False is written in the tachyarrhythmia prevention / treatment mode flag of the vagal nerve tachycardia prevention unit 55 (step S127). S128) Then, the defibrillation therapy by the defibrillator 32 connected by the antitachycardia therapy output switching unit 33 is supplied to the heart 38 via the shock pulse generator 11 (S128). Step S 1 2 9).
- the tachycardia determines whether or not the tachycardia has stopped (step S130), and if it is confirmed that the tachycardia has stopped, the tachycardia prevention of the timing unit 8 is performed.
- the treatment switching timer 20 is reset / started (step S1311), and then the bradycardia treatment switching timer 25 of the bradycardia treatment unit 9 is reset / started (step S13). 13 2), the second bradycardia treatment mode of the second bradycardia treatment section 24 is selected by the bradycardia treatment selection section 28 (step S 13 33), and the judgment step S of FIG. Return to 1 1 1.
- the process returns to the step S110 of FIG. 12 to select the tachyarrhythmia stop treatment again. Based on a predetermined treatment plan, the applied energy is increased and the treatment for stopping tachycardia is changed in stages.
- step S134 If the continuation of the tachycardia is not confirmed in the judgment steps S122 and S126, that is, if the tachycardia stops spontaneously during charging of the capacitor of the shock pulse generator 11, charging is performed. Stop, internal discharge of charging energy, cardiopurge of tachycardia stop 1 2 The connection between the shock section 31 or the defibrillation section 32 and the shock pulse generation section 11 is disconnected, and the tachycardia prevention / treatment mode flag of the vagus nerve stimulation tachycardia prevention section 55 is True. It is determined whether or not it is (step S134).
- the tachycardia preventive treatment mode flag is True, that is, when the stimulation frequency f1 of the first operation mode is selected in the tachycardia preventive treatment of the vagus nerve stimulation tachycardia preventive unit 55, FIG.
- the tachycardia preventive treatment mode flag is not True, that is, in the tachyarrhythmia preventive treatment of the vagus nerve stimulation tachycardia preventive unit 55, the stimulation frequency f 2 of the second operation mode is used. Is selected, it is highly probable that the heart is still in an unstable state, and the sequence after step S131, which is the sequence after the stop of tachycardia, is passed through the tachyarrhythmia stop confirmation unit 5. Perform processing.
- FIG. 14 is a block diagram showing a fifth embodiment of the heart treatment apparatus according to the present invention.
- the configuration of the fifth embodiment of the present invention is almost the same as the configuration of the fourth embodiment of the present invention shown in FIG. 11, and the difference between the configurations is that the first operation mode stimulation frequency is different from that of the fourth embodiment.
- the stimulus frequency of the first operation mode is set in the range of fl to f 2 (f 1> f 2) while the output of the cardiac contraction detection unit 2 is fixed in the fifth embodiment. It is a point that is varied.
- the stimulus frequency f3 in the second operation mode is lower than f2.
- the configuration other than the above components is the same as that of the block configuration diagram in FIG. 11, so the same reference numerals are given and the description is omitted.
- the mode in response to the detection of the tachycardia, the mode is shifted to the mode with the smallest stimulation energy by changing only the stimulation frequency among the parameters of the nerve stimulation signal.
- the stimulation frequency at least one of the stimulation frequency, pulse width, number of pulses, pulse current, pulse voltage, delay time, pause time, and number of repetitions is used as the parameter of the neural stimulation signal. Or from among these It is also possible to shift to the mode with the smallest stimulation energy by changing the selected parameters.
- the selection unit 58 of the vagus nerve stimulation tachycardia prevention unit 55 selects the stimulus frequency (fl to f2) of the first operation mode as an initial value, and sets a relatively low energy within this frequency range.
- the vagus nerve 41 is stimulated with a high stimulation waveform (step S135).
- True is written in a tachyarrhythmia prevention / treatment mode flag (not shown) of the vagus nerve stimulation tachycardia prevention unit 55 (step S136).
- the timing section 8 stops / resets the tachycardia prophylaxis treatment switching timer 20 (step S 1337), and the bradycardia treatment section 9 sets the bradycardia treatment selection section 28.
- the first bradycardia therapy mode of the first bradycardia therapy section 23 is selected (step S138), and the bradycardia therapy switching timer 25 is reset. (Step S13 9).
- Step S140 it is determined whether or not a bradycardia is detected by the cardiac contraction detecting section 2 (Step S140), and if a bradycardia is detected, the pacing pulse generating section 10 determines whether or not the bradycardia is detected.
- the bradycardia therapy is supplied to the heart 38 (step S144). If the bradycardia is not detected in the determination step S140, then it is determined whether the tachycardia is detected by the tachycardia detector 3 (step S144), and the tachycardia is detected.
- a signal is sent to tachyarrhythmia stop section 12 to select tachyarrhythmia arrest treatment corresponding to the detected tachycardia from among anti-tachycardia pacing, cardioversion, and defibrillation (Step S144). After that, go to 5A in Figure 16.
- step S141 a decision was made as to whether bradycardia therapy was supplied. If no tachycardia is detected in step S144, it is determined whether or not the tachycardia preventive treatment switching timer 20 of the timing unit 8 has timed out (step S144). If the tachycardia preventive treatment switching timer 20 has timed out, that is, if the timer measured by the tachycardia preventive treatment switching timer 20 exceeds the time stored in the switching time storage unit 21, control is performed.
- a signal is sent to the selection unit 58 through the second control unit 63 of the unit 7 to give a relatively strong stimulation to the vagus nerve 41, so that the stimulation frequency of the first operation mode (fl to f2) Is selected (step S145), True is written in the tachycardia prevention treatment mode flag of the vagus nerve stimulation tachycardia prevention unit 55 (step S144), and then tachycardia prevention is performed. Stop / reset the treatment switching timer 20 (step S144).
- the tachycardia preventive treatment switching timer 20 is stopped in the step S147.
- whether the bradycardia therapy switching timer 25 in the bradycardia therapy section 9 has timed out that is, the bradycardia therapy switching timer 25 is stored in the bradycardia therapy switching time storage section 26 It is determined whether or not the time has been measured beyond the stored time (step S148).
- the process returns to the selection of the first bradycardia treatment mode in step S138, and the bradycardia treatment switching timer 25 If has not timed out, in decision step S140, a new bradycardia detection is awaited.
- step S144 After 5A, the operation of the fifth embodiment of the present invention after the selection of the tachyarrhythmia arrest treatment in step S144 (after 5A) will be described with reference to the flowchart of FIG.
- Step S 1 4 9 it is determined whether the anti-tachycardia pacing treatment is selected as the anti-tachycardia treatment (tachyarrhythmia treatment) in the tachycardia arresting unit 12 (Step S 1 4 9).
- the anti-tachycardia pacing treatment is selected, the first control unit 62 of the control unit 7 is operated, and the selection unit 58 of the vagus nerve stimulation tachycardia prevention unit 55 selects the second operation mode. Simultaneously with the selection of the stimulation frequency f3 (step S150), False is written in the tachyarrhythmia prevention / treatment mode flag of the vagus nerve stimulation tachycardia prevention unit 55 (step S1501).
- the anti-tachycardia therapy output switching unit 33 of the tachycardia stop unit 12 connects the anti-tachycardia pacing unit 30 and the pacing pulse generator 10 to perform anti-tachycardia pacing on the heart 38.
- step S153 it is judged whether or not the cardiopurgeon treatment is selected.
- the anti-tachycardia treatment output switching unit 33 of the tachycardia stop unit 12 connects the cardioversion unit 31 and the shock pulse generation unit 11 and the shock pulse generation unit 11 A predetermined amount of energy corresponding to the power version treatment is charged to the capacitors.
- the tachycardia checking unit 4 checks whether or not the tachycardia continues (step S 15 4), and determines that the tachycardia continues.
- a signal is sent from the first control section 62 of the control section 7 to the selection section 58 of the vagus nerve stimulation tachycardia prevention section 55, and the selection section 58 selects the second operation mode. Is selected (step S155), False is written to the tachyarrhythmia preventive treatment mode flag of the vagus nerve stimulation tachycardia prevention unit 55 (step S155), and then Then, the cardioversion treatment by the cardioversion unit 31 connected by the anti-tachycardia treatment output switching unit 33 is supplied to the heart 38 via the shock pulse generation unit 11 (step S157).
- the anti-tachycardia pacing treatment is not selected.
- the cardioversion treatment is not selected in the judgment step S153, that is, when the defibrillation treatment is selected (step S158)
- the anti-tachycardia treatment output switching unit of the tachycardia stop unit 12 is selected.
- the connection 33 connects the defibrillator 3 2 and the shock pulse generator 11, and the capacitor of the shock pulse generator 11 is charged with a predetermined amount of energy corresponding to the defibrillation treatment.
- the tachycardia checking unit 4 checks whether or not the tachycardia continues (step S159).
- a signal is sent from the first control unit 62 of the control unit 7 to the selection unit 58 of the vagus nerve stimulation tachycardia prevention unit 55, and the second When the stimulation frequency f3 of the operation mode is selected (step S160), False is written in the tachyarrhythmia prevention / treatment mode flag of the vagal nerve tachycardia prevention unit 55 (step S160).
- step S160 False is written in the tachyarrhythmia prevention / treatment mode flag of the vagal nerve tachycardia prevention unit 55.
- the defibrillation treatment by the defibrillation unit 32 connected by the anti-tachycardia treatment output switching unit 33 is supplied to the heart 38 via the shock pulse generation unit 11 ( Step S1 62).
- the tachycardia determines whether or not the tachycardia has stopped (step S1663). If it is confirmed that the tachycardia has stopped, the tachycardia preventive treatment of the timing unit 8 is performed.
- the switching timer 20 is reset / started (step S1664), and then the bradycardia treatment switching timer 25 of the bradycardia treatment unit 9 is reset / started (step S16). 16 5), the second bradycardia treatment mode of the second bradycardia treatment section 24 is selected by the bradycardia treatment selection section 28 (step S 1666), and the judgment step S of FIG. Return to 1 4 4.
- the process returns to the step S 1 43 of FIG. 15 to select the tachyarrhythmia stop treatment again.
- the applied energy is increased and the tachyarrhythmia arrest treatment is changed stepwise based on a predetermined treatment plan.
- the tachycardia stopped spontaneously during charging of the capacitor of the shock pulse generator 11
- the charging is stopped and the internal discharge of the charging energy is performed, and the connection between the cardiopurge ion unit 31 or the defibrillation unit 32 of the tachycardia stopping unit 12 and the shock pulse generating unit 11 is released.
- the tachyarrhythmia prevention / treatment mode flag of the vagus nerve stimulation tachycardia prevention unit 55 is True (step S167).
- the tachycardia preventive treatment mode flag is True, that is, the stimulation frequency (fl to f2) of the first operation mode is selected in the tachycardia preventive treatment of the vagus nerve stimulation tachycardia preventive unit 55.
- the flow returns to the judgment step S144 of FIG. If f 3 is selected, it is highly probable that the heart is still in an unstable state, and the sequence after the stop of tachycardia via the tachyarrhythmia stop confirmation unit 5 is performed. The following processing is performed.
- the activation current to the vagus nerve or the sympathetic nerve after the arrhythmia treatment such as electric shock to the heart such as cardioversion treatment or defibrillation treatment.
- a control mechanism to reduce or stop the suppression current for the tachycardia, and respond to tachycardia detection or confirmation of tachycardia Stopping force The system can shift to a mode with low nerve stimulation energy, which solves problems such as deterioration of hemodynamics, reoccurrence of fatal arrhythmias, and supraventricular arrhythmias such as atrial fibrillation. can do.
Landscapes
- Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Electrotherapy Devices (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Abstract
Description
Claims
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/558,421 US20070100380A1 (en) | 2003-05-30 | 2004-05-26 | Heart treatment equipment and heart treatment method |
| EP04734945A EP1640035A4 (en) | 2003-05-30 | 2004-05-26 | HEART TREATMENT APPARATUS AND HEART TREATMENT METHOD |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003155531A JP4213522B2 (ja) | 2003-05-30 | 2003-05-30 | 心臓治療装置 |
| JP2003-155531 | 2003-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2004105870A1 true WO2004105870A1 (ja) | 2004-12-09 |
Family
ID=33487363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2004/007568 Ceased WO2004105870A1 (ja) | 2003-05-30 | 2004-05-26 | 心臓治療装置及び心臓治療方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20070100380A1 (ja) |
| EP (1) | EP1640035A4 (ja) |
| JP (1) | JP4213522B2 (ja) |
| WO (1) | WO2004105870A1 (ja) |
Cited By (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006288837A (ja) * | 2005-04-12 | 2006-10-26 | Univ Nagoya | 除細動装置 |
| JP2006288838A (ja) * | 2005-04-12 | 2006-10-26 | Univ Nagoya | 細動防止装置 |
| WO2006121836A1 (en) * | 2005-05-05 | 2006-11-16 | Cardiac Pacemakers, Inc. | Device for comprehensive anti-tachyarrhythmia therapy |
| US7194313B2 (en) | 2003-12-24 | 2007-03-20 | Cardiac Pacemakers, Inc. | Baroreflex therapy for disordered breathing |
| US7460906B2 (en) | 2003-12-24 | 2008-12-02 | Cardiac Pacemakers, Inc. | Baroreflex stimulation to treat acute myocardial infarction |
| US7509166B2 (en) | 2003-12-24 | 2009-03-24 | Cardiac Pacemakers, Inc. | Automatic baroreflex modulation responsive to adverse event |
| US7555341B2 (en) | 2005-04-05 | 2009-06-30 | Cardiac Pacemakers, Inc. | System to treat AV-conducted ventricular tachyarrhythmia |
| US7570999B2 (en) | 2005-12-20 | 2009-08-04 | Cardiac Pacemakers, Inc. | Implantable device for treating epilepsy and cardiac rhythm disorders |
| EP1870131A4 (en) * | 2005-04-12 | 2009-10-21 | Univ Nagoya Nat Univ Corp | DEVICE FOR AVOIDING VENTRICULAR FIBRILLATION AND DEVICE ELIMINATING VENTRICULAR FIBRILLATION |
| US7643875B2 (en) | 2003-12-24 | 2010-01-05 | Cardiac Pacemakers, Inc. | Baroreflex stimulation system to reduce hypertension |
| US7647114B2 (en) | 2003-12-24 | 2010-01-12 | Cardiac Pacemakers, Inc. | Baroreflex modulation based on monitored cardiovascular parameter |
| US7747323B2 (en) | 2004-06-08 | 2010-06-29 | Cardiac Pacemakers, Inc. | Adaptive baroreflex stimulation therapy for disordered breathing |
| US7783353B2 (en) | 2003-12-24 | 2010-08-24 | Cardiac Pacemakers, Inc. | Automatic neural stimulation modulation based on activity and circadian rhythm |
| US7787946B2 (en) | 2003-08-18 | 2010-08-31 | Cardiac Pacemakers, Inc. | Patient monitoring, diagnosis, and/or therapy systems and methods |
| US7869881B2 (en) | 2003-12-24 | 2011-01-11 | Cardiac Pacemakers, Inc. | Baroreflex stimulator with integrated pressure sensor |
| US8000793B2 (en) | 2003-12-24 | 2011-08-16 | Cardiac Pacemakers, Inc. | Automatic baroreflex modulation based on cardiac activity |
| US8002553B2 (en) | 2003-08-18 | 2011-08-23 | Cardiac Pacemakers, Inc. | Sleep quality data collection and evaluation |
| US8024050B2 (en) | 2003-12-24 | 2011-09-20 | Cardiac Pacemakers, Inc. | Lead for stimulating the baroreceptors in the pulmonary artery |
| US8126560B2 (en) | 2003-12-24 | 2012-02-28 | Cardiac Pacemakers, Inc. | Stimulation lead for stimulating the baroreceptors in the pulmonary artery |
| US8131362B2 (en) | 2005-03-11 | 2012-03-06 | Cardiac Pacemakers, Inc. | Combined neural stimulation and cardiac resynchronization therapy |
| US8170668B2 (en) | 2006-07-14 | 2012-05-01 | Cardiac Pacemakers, Inc. | Baroreflex sensitivity monitoring and trending for tachyarrhythmia detection and therapy |
| US8255049B2 (en) | 2006-05-08 | 2012-08-28 | Cardiac Pacemakers, Inc. | Method and device for providing anti-tachyarrhythmia therapy |
| US8606356B2 (en) | 2003-09-18 | 2013-12-10 | Cardiac Pacemakers, Inc. | Autonomic arousal detection system and method |
| US8660648B2 (en) | 2005-10-24 | 2014-02-25 | Cardiac Pacemakers, Inc. | Implantable and rechargeable neural stimulator |
| US8805494B2 (en) | 2005-05-10 | 2014-08-12 | Cardiac Pacemakers, Inc. | System and method to deliver therapy in presence of another therapy |
| US8929990B2 (en) | 2005-04-11 | 2015-01-06 | Cardiac Pacemakers, Inc. | Transvascular neural stimulation device and method for treating hypertension |
| US8983598B2 (en) | 2006-10-04 | 2015-03-17 | Cardiac Pacemakers, Inc. | System for neurally-mediated anti-arrhythmic therapy |
| US9020595B2 (en) | 2003-12-24 | 2015-04-28 | Cardiac Pacemakers, Inc. | Baroreflex activation therapy with conditional shut off |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
| JP2007530586A (ja) | 2004-03-25 | 2007-11-01 | ザ ファインスタイン インスティテュート フォー メディカル リサーチ | 神経性止血法 |
| US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
| US7277750B2 (en) | 2004-04-02 | 2007-10-02 | Cardiac Pacemakers, Inc. | Method and apparatus for anti-tachycardia pacing and defibrillation |
| US8010192B2 (en) | 2004-12-20 | 2011-08-30 | Cardiac Pacemakers, Inc. | Endocardial pacing relating to conduction abnormalities |
| US8050756B2 (en) | 2004-12-20 | 2011-11-01 | Cardiac Pacemakers, Inc. | Circuit-based devices and methods for pulse control of endocardial pacing in cardiac rhythm management |
| AR047851A1 (es) | 2004-12-20 | 2006-03-01 | Giniger Alberto German | Un nuevo marcapasos que restablece o preserva la conduccion electrica fisiologica del corazon y un metodo de aplicacion |
| US8290586B2 (en) | 2004-12-20 | 2012-10-16 | Cardiac Pacemakers, Inc. | Methods, devices and systems for single-chamber pacing using a dual-chamber pacing device |
| US8010191B2 (en) | 2004-12-20 | 2011-08-30 | Cardiac Pacemakers, Inc. | Systems, devices and methods for monitoring efficiency of pacing |
| US8014861B2 (en) | 2004-12-20 | 2011-09-06 | Cardiac Pacemakers, Inc. | Systems, devices and methods relating to endocardial pacing for resynchronization |
| US8326423B2 (en) | 2004-12-20 | 2012-12-04 | Cardiac Pacemakers, Inc. | Devices and methods for steering electrical stimulation in cardiac rhythm management |
| US8423139B2 (en) | 2004-12-20 | 2013-04-16 | Cardiac Pacemakers, Inc. | Methods, devices and systems for cardiac rhythm management using an electrode arrangement |
| US8005544B2 (en) | 2004-12-20 | 2011-08-23 | Cardiac Pacemakers, Inc. | Endocardial pacing devices and methods useful for resynchronization and defibrillation |
| CN101124012B (zh) | 2004-12-27 | 2012-09-05 | 范因斯坦医学研究院 | 通过电刺激迷走神经治疗炎症性疾病的装置 |
| US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
| US7660628B2 (en) * | 2005-03-23 | 2010-02-09 | Cardiac Pacemakers, Inc. | System to provide myocardial and neural stimulation |
| US7881782B2 (en) | 2005-04-20 | 2011-02-01 | Cardiac Pacemakers, Inc. | Neural stimulation system to prevent simultaneous energy discharges |
| JPWO2007063900A1 (ja) * | 2005-11-30 | 2009-05-07 | 国立循環器病センター総長 | 身体表面刺激治療装置ならびに身体表面刺激治療プログラムおよびこれを記録したコンピュータ読み取り可能な記録媒体 |
| US8706212B2 (en) * | 2006-12-13 | 2014-04-22 | Cardiac Pacemakers, Inc. | Neural stimulation systems, devices and methods |
| US8391970B2 (en) | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
| WO2009146030A1 (en) | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
| US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
| US8244350B2 (en) | 2008-08-05 | 2012-08-14 | Cardiac Pacemakers, Inc. | Neural stimulation for arrhythmia recognition and therapy |
| US8386053B2 (en) * | 2008-10-31 | 2013-02-26 | Medtronic, Inc. | Subclavian ansae stimulation |
| US8412338B2 (en) | 2008-11-18 | 2013-04-02 | Setpoint Medical Corporation | Devices and methods for optimizing electrode placement for anti-inflamatory stimulation |
| US20100228310A1 (en) * | 2009-03-09 | 2010-09-09 | Shuros Allan C | Systems and methods for autonomic nerve modulation |
| US8788034B2 (en) | 2011-05-09 | 2014-07-22 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
| CN102573986B (zh) | 2009-06-09 | 2016-01-20 | 赛博恩特医疗器械公司 | 用于无导线刺激器的具有袋部的神经封套 |
| JP5734555B2 (ja) | 2009-10-15 | 2015-06-17 | オリンパス株式会社 | 神経刺激装置 |
| US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
| US11051744B2 (en) | 2009-11-17 | 2021-07-06 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
| US8548585B2 (en) | 2009-12-08 | 2013-10-01 | Cardiac Pacemakers, Inc. | Concurrent therapy detection in implantable medical devices |
| CN102821814B (zh) | 2009-12-23 | 2015-07-15 | 赛博恩特医疗器械公司 | 用于治疗慢性炎症的神经刺激设备和系统 |
| US12172017B2 (en) | 2011-05-09 | 2024-12-24 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| US20150111918A1 (en) | 2012-03-08 | 2015-04-23 | Medtronic Ardian Luxembourg S.a.r.l | Immune system neuromodulation and associated systems and methods |
| US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
| US11097107B2 (en) | 2012-05-31 | 2021-08-24 | Zoll Medical Corporation | External pacing device with discomfort management |
| US10328266B2 (en) | 2012-05-31 | 2019-06-25 | Zoll Medical Corporation | External pacing device with discomfort management |
| EP2854940B1 (en) | 2012-05-31 | 2022-07-06 | Zoll Medical Corporation | Medical monitoring and treatment device with external pacing |
| US9643011B2 (en) * | 2013-03-14 | 2017-05-09 | Cyberonics, Inc. | Implantable neurostimulator-implemented method for managing tachyarrhythmic risk during sleep through vagus nerve stimulation |
| US9744364B2 (en) * | 2013-09-25 | 2017-08-29 | Medtronic, Inc. | Method and apparatus for automatic configuration of implantable medical devices |
| US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
| EP3226795B1 (en) | 2014-12-03 | 2020-08-26 | Metavention, Inc. | Systems for modulating nerves or other tissue |
| WO2016126807A1 (en) | 2015-02-03 | 2016-08-11 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
| US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
| EP3405107B1 (en) | 2016-01-20 | 2023-04-12 | Setpoint Medical Corporation | Control of vagal stimulation |
| EP3405255B1 (en) | 2016-01-20 | 2025-12-31 | Setpoint Medical Corporation | IMPLANTABLE MICROSTIMULATORS AND INDUCTION CHARGING SYSTEMS |
| US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
| US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
| US10524859B2 (en) | 2016-06-07 | 2020-01-07 | Metavention, Inc. | Therapeutic tissue modulation devices and methods |
| WO2019036470A1 (en) | 2017-08-14 | 2019-02-21 | Setpoint Medical Corporation | TESTING TEST FOR STIMULATION OF NERVE WAVE |
| US10675471B2 (en) | 2017-08-15 | 2020-06-09 | Medtronic, Inc. | Anti-tachycardia pacing control in an implantable medical device system |
| US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
| AU2020272128B9 (en) | 2019-04-12 | 2025-11-20 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| JP2023512447A (ja) | 2020-01-13 | 2023-03-27 | ザ ファインスタイン インスティチューツ フォー メディカル リサーチ | 脾臓への高密度集束超音波刺激による出血及び出血性疾患の治療 |
| WO2021236977A1 (en) | 2020-05-21 | 2021-11-25 | The Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
| WO2022245878A1 (en) | 2021-05-17 | 2022-11-24 | Setpoint Medical Corporation | Neurostimulation parameter authentication and expiration system for neurostimulation |
| US20250229086A1 (en) | 2022-01-20 | 2025-07-17 | Setpoint Medical Corporation | Treatment of inflammatory disorders |
| EP4547321A1 (en) | 2022-07-01 | 2025-05-07 | Artha Partners B.V. | Systems and methods of denervation around subclavian arteries |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0838626A (ja) * | 1994-06-24 | 1996-02-13 | Pacesetter Ab | 上室心臓治療装置 |
| JPH11514268A (ja) * | 1995-10-13 | 1999-12-07 | ザバラ,ジェイコブ | ニューロサイバネチックプロテーゼを使用する心臓律動の安定化 |
| JP2002534233A (ja) * | 1999-01-14 | 2002-10-15 | ザ モウアー ファミリー シーエイチエフ トリートメント イレボケィブル トラスト | 頻脈予防の心搏調整 |
| JP2003511163A (ja) * | 1999-10-13 | 2003-03-25 | サイベロニクス,インク. | 心不全の患者の心臓毛細管の発達を促す方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5063928A (en) * | 1990-07-05 | 1991-11-12 | Telectronics Pacing Systems, Inc. | Apparatus and method for detecting and treating cardiac tachyarrhythmias |
| US5292339A (en) * | 1991-06-14 | 1994-03-08 | Telectronics Pacing Systems, Inc. | Implantable pacemaker/cardioverter/defibrillator device and method incorporating multiple bradycardia support pacing rates |
| EP0688579B1 (en) * | 1994-06-24 | 2001-08-22 | St. Jude Medical AB | Device for heart therapy |
| US5549641A (en) * | 1994-10-31 | 1996-08-27 | Incontrol, Inc. | Atrial fibrillation type selective cardiovertor and method |
| US6337995B1 (en) * | 1996-08-19 | 2002-01-08 | Mower Chf Treatment Irrevocable Trust | Atrial sensing and multiple site stimulation as intervention for atrial fibrillation |
| US6134470A (en) * | 1998-11-09 | 2000-10-17 | Medtronic, Inc. | Method and apparatus for treating a tachyarrhythmic patient |
| US6272377B1 (en) * | 1999-10-01 | 2001-08-07 | Cardiac Pacemakers, Inc. | Cardiac rhythm management system with arrhythmia prediction and prevention |
| US6487450B1 (en) * | 2000-02-24 | 2002-11-26 | Cedars-Sinai Medical Center | System and method for preventing Sudden Cardiac Death by nerve sprouting from right stellate ganglion |
| US6895273B2 (en) * | 2001-04-06 | 2005-05-17 | Cardiac Pacemakers, Inc. | Temporary tachyarrhythmia therapy modes for electrophysiologic testing |
| US7778703B2 (en) * | 2001-08-31 | 2010-08-17 | Bio Control Medical (B.C.M.) Ltd. | Selective nerve fiber stimulation for treating heart conditions |
-
2003
- 2003-05-30 JP JP2003155531A patent/JP4213522B2/ja not_active Expired - Fee Related
-
2004
- 2004-05-26 WO PCT/JP2004/007568 patent/WO2004105870A1/ja not_active Ceased
- 2004-05-26 US US10/558,421 patent/US20070100380A1/en not_active Abandoned
- 2004-05-26 EP EP04734945A patent/EP1640035A4/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0838626A (ja) * | 1994-06-24 | 1996-02-13 | Pacesetter Ab | 上室心臓治療装置 |
| JPH11514268A (ja) * | 1995-10-13 | 1999-12-07 | ザバラ,ジェイコブ | ニューロサイバネチックプロテーゼを使用する心臓律動の安定化 |
| JP2002534233A (ja) * | 1999-01-14 | 2002-10-15 | ザ モウアー ファミリー シーエイチエフ トリートメント イレボケィブル トラスト | 頻脈予防の心搏調整 |
| JP2003511163A (ja) * | 1999-10-13 | 2003-03-25 | サイベロニクス,インク. | 心不全の患者の心臓毛細管の発達を促す方法 |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP1640035A4 * |
Cited By (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7787946B2 (en) | 2003-08-18 | 2010-08-31 | Cardiac Pacemakers, Inc. | Patient monitoring, diagnosis, and/or therapy systems and methods |
| US8915741B2 (en) | 2003-08-18 | 2014-12-23 | Cardiac Pacemakers, Inc. | Sleep quality data collection and evaluation |
| US8002553B2 (en) | 2003-08-18 | 2011-08-23 | Cardiac Pacemakers, Inc. | Sleep quality data collection and evaluation |
| US8606356B2 (en) | 2003-09-18 | 2013-12-10 | Cardiac Pacemakers, Inc. | Autonomic arousal detection system and method |
| US9014819B2 (en) | 2003-09-18 | 2015-04-21 | Cardiac Pacemakers, Inc. | Autonomic arousal detection system and method |
| US8874211B2 (en) | 2003-12-23 | 2014-10-28 | Cardiac Pacemakers, Inc. | Hypertension therapy based on activity and circadian rhythm |
| US7643875B2 (en) | 2003-12-24 | 2010-01-05 | Cardiac Pacemakers, Inc. | Baroreflex stimulation system to reduce hypertension |
| US8126560B2 (en) | 2003-12-24 | 2012-02-28 | Cardiac Pacemakers, Inc. | Stimulation lead for stimulating the baroreceptors in the pulmonary artery |
| US9561373B2 (en) | 2003-12-24 | 2017-02-07 | Cardiac Pacemakers, Inc. | System to stimulate a neural target and a heart |
| US8805501B2 (en) | 2003-12-24 | 2014-08-12 | Cardiac Pacemakers, Inc. | Baroreflex stimulation to treat acute myocardial infarction |
| US7647114B2 (en) | 2003-12-24 | 2010-01-12 | Cardiac Pacemakers, Inc. | Baroreflex modulation based on monitored cardiovascular parameter |
| US7706884B2 (en) | 2003-12-24 | 2010-04-27 | Cardiac Pacemakers, Inc. | Baroreflex stimulation synchronized to circadian rhythm |
| US9440078B2 (en) | 2003-12-24 | 2016-09-13 | Cardiac Pacemakers, Inc. | Neural stimulation modulation based on monitored cardiovascular parameter |
| US7783353B2 (en) | 2003-12-24 | 2010-08-24 | Cardiac Pacemakers, Inc. | Automatic neural stimulation modulation based on activity and circadian rhythm |
| US10342978B2 (en) | 2003-12-24 | 2019-07-09 | Cardiac Pacemakers, Inc. | Vagus nerve stimulation responsive to a tachycardia precursor |
| US7869881B2 (en) | 2003-12-24 | 2011-01-11 | Cardiac Pacemakers, Inc. | Baroreflex stimulator with integrated pressure sensor |
| US8000793B2 (en) | 2003-12-24 | 2011-08-16 | Cardiac Pacemakers, Inc. | Automatic baroreflex modulation based on cardiac activity |
| US7509166B2 (en) | 2003-12-24 | 2009-03-24 | Cardiac Pacemakers, Inc. | Automatic baroreflex modulation responsive to adverse event |
| US8024050B2 (en) | 2003-12-24 | 2011-09-20 | Cardiac Pacemakers, Inc. | Lead for stimulating the baroreceptors in the pulmonary artery |
| US9314635B2 (en) | 2003-12-24 | 2016-04-19 | Cardiac Pacemakers, Inc. | Automatic baroreflex modulation responsive to adverse event |
| US8121693B2 (en) | 2003-12-24 | 2012-02-21 | Cardiac Pacemakers, Inc. | Baroreflex stimulation to treat acute myocardial infarction |
| US9950170B2 (en) | 2003-12-24 | 2018-04-24 | Cardiac Pacemakers, Inc. | System for providing stimulation pattern to modulate neural activity |
| US8131373B2 (en) | 2003-12-24 | 2012-03-06 | Cardiac Pacemakers, Inc. | Baroreflex stimulation synchronized to circadian rhythm |
| US9265948B2 (en) | 2003-12-24 | 2016-02-23 | Cardiac Pacemakers, Inc. | Automatic neural stimulation modulation based on activity |
| US9020595B2 (en) | 2003-12-24 | 2015-04-28 | Cardiac Pacemakers, Inc. | Baroreflex activation therapy with conditional shut off |
| US7460906B2 (en) | 2003-12-24 | 2008-12-02 | Cardiac Pacemakers, Inc. | Baroreflex stimulation to treat acute myocardial infarction |
| US8195289B2 (en) | 2003-12-24 | 2012-06-05 | Cardiac Pacemakers, Inc. | Baroreflex stimulation system to reduce hypertension |
| US7194313B2 (en) | 2003-12-24 | 2007-03-20 | Cardiac Pacemakers, Inc. | Baroreflex therapy for disordered breathing |
| US8285389B2 (en) | 2003-12-24 | 2012-10-09 | Cardiac Pacemakers, Inc. | Automatic neural stimulation modulation based on motion and physiological activity |
| US10369367B2 (en) | 2003-12-24 | 2019-08-06 | Cardiac Pacemakers, Inc. | System for providing stimulation pattern to modulate neural activity |
| US8442640B2 (en) | 2003-12-24 | 2013-05-14 | Cardiac Pacemakers, Inc. | Neural stimulation modulation based on monitored cardiovascular parameter |
| US8818513B2 (en) | 2003-12-24 | 2014-08-26 | Cardiac Pacemakers, Inc. | Baroreflex stimulation synchronized to circadian rhythm |
| US8457746B2 (en) | 2003-12-24 | 2013-06-04 | Cardiac Pacemakers, Inc. | Implantable systems and devices for providing cardiac defibrillation and apnea therapy |
| US8473076B2 (en) | 2003-12-24 | 2013-06-25 | Cardiac Pacemakers, Inc. | Lead for stimulating the baroreceptors in the pulmonary artery |
| US11154716B2 (en) | 2003-12-24 | 2021-10-26 | Cardiac Pacemakers, Inc. | System for providing stimulation pattern to modulate neural activity |
| US8626301B2 (en) | 2003-12-24 | 2014-01-07 | Cardiac Pacemakers, Inc. | Automatic baroreflex modulation based on cardiac activity |
| US8639322B2 (en) | 2003-12-24 | 2014-01-28 | Cardiac Pacemakers, Inc. | System and method for delivering myocardial and autonomic neural stimulation |
| US8805513B2 (en) | 2003-12-24 | 2014-08-12 | Cardiac Pacemakers, Inc. | Neural stimulation modulation based on monitored cardiovascular parameter |
| US8442638B2 (en) | 2004-06-08 | 2013-05-14 | Cardiac Pacemakers, Inc. | Adaptive baroreflex stimulation therapy for disordered breathing |
| US9872987B2 (en) | 2004-06-08 | 2018-01-23 | Cardiac Pacemakers, Inc. | Method and system for treating congestive heart failure |
| US7747323B2 (en) | 2004-06-08 | 2010-06-29 | Cardiac Pacemakers, Inc. | Adaptive baroreflex stimulation therapy for disordered breathing |
| US8131362B2 (en) | 2005-03-11 | 2012-03-06 | Cardiac Pacemakers, Inc. | Combined neural stimulation and cardiac resynchronization therapy |
| US8190257B2 (en) | 2005-04-05 | 2012-05-29 | Cardiac Pacemakers, Inc. | System to treat AV-conducted ventricular tachyarrhythmia |
| US8909337B2 (en) | 2005-04-05 | 2014-12-09 | Cardiac Pacemakers, Inc. | System to treat AV-conducted ventricular tachyarrhythmia |
| US7555341B2 (en) | 2005-04-05 | 2009-06-30 | Cardiac Pacemakers, Inc. | System to treat AV-conducted ventricular tachyarrhythmia |
| US8929990B2 (en) | 2005-04-11 | 2015-01-06 | Cardiac Pacemakers, Inc. | Transvascular neural stimulation device and method for treating hypertension |
| JP2006288838A (ja) * | 2005-04-12 | 2006-10-26 | Univ Nagoya | 細動防止装置 |
| JP2006288837A (ja) * | 2005-04-12 | 2006-10-26 | Univ Nagoya | 除細動装置 |
| EP1870131A4 (en) * | 2005-04-12 | 2009-10-21 | Univ Nagoya Nat Univ Corp | DEVICE FOR AVOIDING VENTRICULAR FIBRILLATION AND DEVICE ELIMINATING VENTRICULAR FIBRILLATION |
| WO2006121836A1 (en) * | 2005-05-05 | 2006-11-16 | Cardiac Pacemakers, Inc. | Device for comprehensive anti-tachyarrhythmia therapy |
| US8055340B2 (en) | 2005-05-05 | 2011-11-08 | Cardiac Pacemakers, Inc. | Method and device for comprehensive anti-tachyarrhythmia therapy |
| US8452401B2 (en) | 2005-05-05 | 2013-05-28 | Cardiac Pacemakers, Inc. | Method and device for comprehensive anti-tachyarrhythmia therapy |
| US8805494B2 (en) | 2005-05-10 | 2014-08-12 | Cardiac Pacemakers, Inc. | System and method to deliver therapy in presence of another therapy |
| US9504836B2 (en) | 2005-05-10 | 2016-11-29 | Cardiac Pacemakers, Inc. | System and method to deliver therapy in presence of another therapy |
| US8660648B2 (en) | 2005-10-24 | 2014-02-25 | Cardiac Pacemakers, Inc. | Implantable and rechargeable neural stimulator |
| US7570999B2 (en) | 2005-12-20 | 2009-08-04 | Cardiac Pacemakers, Inc. | Implantable device for treating epilepsy and cardiac rhythm disorders |
| US8255049B2 (en) | 2006-05-08 | 2012-08-28 | Cardiac Pacemakers, Inc. | Method and device for providing anti-tachyarrhythmia therapy |
| US9084898B2 (en) | 2006-05-08 | 2015-07-21 | Cardiac Pacemakers, Inc. | Method and device for providing anti-tachyarrhythmia therapy |
| US8170668B2 (en) | 2006-07-14 | 2012-05-01 | Cardiac Pacemakers, Inc. | Baroreflex sensitivity monitoring and trending for tachyarrhythmia detection and therapy |
| US8983598B2 (en) | 2006-10-04 | 2015-03-17 | Cardiac Pacemakers, Inc. | System for neurally-mediated anti-arrhythmic therapy |
Also Published As
| Publication number | Publication date |
|---|---|
| US20070100380A1 (en) | 2007-05-03 |
| EP1640035A4 (en) | 2009-03-18 |
| JP2004351122A (ja) | 2004-12-16 |
| JP4213522B2 (ja) | 2009-01-21 |
| EP1640035A1 (en) | 2006-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004105870A1 (ja) | 心臓治療装置及び心臓治療方法 | |
| US11097106B2 (en) | Implantable neurostimulator-implemented method for managing tachyarrhythmia through vagus nerve stimulation | |
| JP4262596B2 (ja) | 埋め込み可能医療デバイスにおいて高電圧および抗頻脈ペーシング治療の送出を制御する方法および装置 | |
| US6330477B1 (en) | Ventricular synchronized atrial pacing mode of implantable cardioverter/defibrillator | |
| US6134470A (en) | Method and apparatus for treating a tachyarrhythmic patient | |
| US7317942B2 (en) | Dynamic discrimination utilizing anti-tachy pacing therapy in an implantable medical device | |
| US8452401B2 (en) | Method and device for comprehensive anti-tachyarrhythmia therapy | |
| JPH09122250A (ja) | 植え込み可能な心臓刺激装置 | |
| JP2006504486A (ja) | 埋め込み可能医療デバイス | |
| WO2004084990A1 (ja) | 心臓治療装置及び心臓治療方法 | |
| JP4937903B2 (ja) | 埋め込み可能医療デバイスにおいて高電圧及び抗頻脈ペーシング治療の送出を制御する方法及び装置 | |
| US7184831B2 (en) | Method and apparatus to control delivery of high-voltage and anti-tachy pacing therapy in an implantable medical device | |
| JP2005512696A (ja) | 心臓ペーシングの方法およびシステム | |
| JP4863991B2 (ja) | 同調監視付きatpペーシング | |
| US20230149725A1 (en) | Implantable medical devices for combination treatments | |
| EP1735051A1 (en) | Device for hemodynamic stabilization during tachycardias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2004734945 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2004734945 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2007100380 Country of ref document: US Ref document number: 10558421 Country of ref document: US |
|
| WWP | Wipo information: published in national office |
Ref document number: 10558421 Country of ref document: US |